Live Breaking News & Updates on ப்ராடக்ட்ஸ் பொறுப்பு வழக்கு

Tuesday, January 12, 2021
A judge in the United States District Court for the Southern District of Florida presiding over the 
In Re: Zantac (Ranitidine) Products Liability Litigation multidistrict litigation, MDL No. 2924, has held that state labeling and design defect claims against the makers, re-packagers, retailers, and distributors of generic forms for the popular heartburn medication Zantac were preempted by federal law.  The court subsequently dismissed these claims against 32 such Zantac generics makers and distributors.
The Zantac MDL was created by the United States Judicial Panel on Multidistrict Litigation on February 6, 2020.  The plaintiffs allege that ranitidine, the active ingredient in Zantac and its generic forms, breaks down into N-nitrosodimethylamine (“NDMA”), which is part of a group of compounds that have been shown to increase the risk of cancer. The plaintiffs allege a variety of product liability and related claims against t ....

United States , Supreme Court , Mutual Pharmaceutical Co , United States District Court , Pliva Inc , Southern District , Products Liability Litigation , United States Judicial Panel , Multidistrict Litigation , Mutual Pharmaceutical , 11th Circuit , Zantac Mdl Case , ஒன்றுபட்டது மாநிலங்களில் , உச்ச நீதிமன்றம் , பரஸ்பர மருந்து இணை , ஒன்றுபட்டது மாநிலங்களில் மாவட்டம் நீதிமன்றம் , தெற்கு மாவட்டம் , ப்ராடக்ட்ஸ் பொறுப்பு வழக்கு , ஒன்றுபட்டது மாநிலங்களில் நீதித்துறை குழு , பரஸ்பர மருந்து ,